Picture EBD Group BIO-Europe Spring 2019 BES Wien Vienna Austria 600x60px
Document › Details

Poxel S.A.. (3/4/16). "Press Release: Poxel to Present at 28th Annual Roth Conference". Lyon.

Organisations Organisation Poxel S.A. (Euronext: POXEL)
  Organisation 2 Roth Capital Partners LLC
Products Product Roth Capital Partners Annual Conference 2016 Dana Point, CA
  Product 2 imeglimin
Index term Index term Poxel–Roth Capital Partners: investor conference, 201603 supply service Poxel presents at Annual Roth Conference in Dana Point CA
Persons Person Schweitzer, Gretchen (Trophic Comunications 201801 before MacDougall European Office)
  Person 2 Merigeau, Nicolas (NewCap 201502)

POXEL SA (Euronext – POXEL - FR0012432516), a biopharmaceutical company focused on the development of innovative drugs to treat type 2 diabetes, today announced that the Company will make a presentation at the 28th Annual ROTH Conference to be held on March 13 - 16, 2016 at the Ritz Carlton Hotel, Dana Point, California.

The Company’s management will present on Tuesday, March 15, 2016 at 12:00 p.m. PT / 3:00 p.m. EST/ 9:00 p.m. CET.

The simultaneous live webcast, including a slide presentation, can be accessed by logging onto or on the Poxel website at A replay of the webcast will be available on Poxel’s website shortly after the conclusion of the call and will be archived there for 30 days following the call.

About Poxel SA

Poxel uses its unique development expertise in metabolism to advance a pipeline of truly novel products currently focused on type 2 diabetes. Our first-in-class lead product, Imeglimin, targeting mitochondrial dysfunction, has successfully completed Phase 2 development in the US and EU and has started Phase 2b development in Japanese patients. We are advancing our second program, PXL770, a direct AMPK activator, through clinical proof-of-concept. We will generate further growth through strategic partnerships and pipeline development. (Euronext: POXEL,


Investor relations / Media - EU/US
MacDougall Biomedical Communications
Gretchen Schweitzer or Stephanie May
+49 89 2424 3494 or + 49 172 861 8540

Investor relations / Media - France
Florent Alba/Nicolas Merigeau
+33 1 44 71 98 55

Record changed: 2017-07-02


Picture EBD Group BIO-Europe Spring 2019 BES Wien Partnering Opens 600x60px

More documents for Poxel S.A. (Euronext: POXEL)

To subscribe to our free, monthly newsletter for the European life sciences, please send an e-mail to and simply fill the subject line with the word »LSE Newsletter«

To get even more information, please take a look at our [gs] professional services offering and read the gene-sensor Product Flyer [PDF file]


Picture [LSUS] – The Business Web Portal 600x60px

» top